Known targets — ChEMBL curated mechanism
GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQ
The experimentally established mechanism targets of Midazolam. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 known ✓ | P14867 | 1/20 | 0.46 |
| ▸ | GABRG2 known ✓ | P18507 | 1/20 | 0.46 |
| ▸ | GABRB3 known ✓ | P28472 | 1/20 | 0.46 |
| ▸ | GABRA5 known ✓ | P31644 | 1/20 | 0.46 |
| ▸ | GABRA3 known ✓ | P34903 | 1/20 | 0.46 |
| ▸ | GABRA2 known ✓ | P47869 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.83 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.83 |
| ▸ | DRD3 | P35462 | 2/20 | 0.83 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.83 |
| ▸ | SLC22A1 | O15245 | 1/20 | 0.83 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.83 |
| ▸ | HTR1A | P08908 | 1/20 | 0.47 |
| ▸ | HTR3A | P46098 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | GHSR | Q92847 | 1/20 | 0.47 |
| ▸ | AURKA | O14965 | 2/20 | 0.46 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Midazolam SCHEMBL8811703 | 1.00 | OPRK1 (0.83) | OPRK1CYP3A4DRD3PDE4DSLC22A1 | |
| Midazolam SCHEMBL413785 | 1.00 | OPRK1 (0.83) | OPRK1CYP3A4DRD3PDE4DSLC22A1 | |
| Midazolam SCHEMBL29565146 | 0.91 | OPRK1 (1.00) | OPRK1CYP3A4DRD3PDE4DSLC22A1 | |
| Midazolam SCHEMBL5783371 | 0.91 | OPRK1 (1.00) | OPRK1CYP3A4DRD3PDE4DSLC22A1 | |
| Midazolam SCHEMBL29357425 | 0.91 | OPRK1 (1.00) | OPRK1CYP3A4DRD3PDE4DSLC22A1 | |
| Midazolam SCHEMBL29480459 | 0.91 | OPRK1 (1.00) | OPRK1CYP3A4DRD3PDE4DSLC22A1 | |
| Midazolam SCHEMBL35061 | 0.91 | OPRK1 (1.00) | OPRK1CYP3A4DRD3PDE4DSLC22A1 | |
| Midazolam SCHEMBL29735381 | 0.91 | OPRK1 (1.00) | OPRK1CYP3A4DRD3PDE4DSLC22A1 | |
| Midazolam SCHEMBL1311204 | 0.90 | OPRK1 (0.98) | OPRK1CYP3A4DRD3PDE4DSLC22A1 | |
| Midazolam SCHEMBL41265 | 0.90 | OPRK1 (0.98) | OPRK1CYP3A4DRD3PDE4DSLC22A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1981 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4687838-A2 | UNIT DOSAGE COMPOSITION COMPRISING MIDAZOLAM | B. Braun Melsungen AG (DE) | 2026-02-11 | — | — | EP | claimed |
| EP-4673122-A1 | ORAL FILM UNIT DOSAGE FORM | SWIPP AB (SE) | 2026-01-07 | — | — | EP | claimed |
| CN-119868290-A | Midazolam maleate orally disintegrating tablet and preparation method thereof | 中国人民解放军总医院第七医学中心 | 2025-04-25 | — | — | CN | claimed |
| WO-2024209420-A2 | UNIT DOSAGE COMPOSITION COMPRISING MIDAZOLAM | B. BRAUN MELSUNGEN AG (DE) | 2024-10-10 | — | — | WO | claimed |
| EP-4442249-A1 | UNIT DOSAGE COMPOSITION COMPRISING MIDAZOLAM | B. Braun Melsungen AG (DE) | 2024-10-09 | — | — | EP | claimed |
| WO-2024180208-A1 | ORAL FILM UNIT DOSAGE FORM | SWIPP AB (SE) | 2024-09-06 | — | — | WO | claimed |
| WO-2023226136-A1 | MICRONEEDLE SYSTEM FOR DIAGNOSIS AND TREATMENT OF BRAIN DISEASES AND PREPARATION METHOD THEREFOR | 深圳先进技术研究院 | 2023-11-30 | — | — | WO | claimed |
| WO-2023078180-A1 | MINI-TABLET, AND PREPARATION METHOD THEREFOR AND FORMULATION THEREOF | 北京微智瑞医药科技有限公司 | 2023-05-11 | — | — | WO | claimed |
| CN-113281422-B | Method for determining 14 illegal sedative and tranquilizing additives in health food | 贵州省产品质量检验检测院 | 2023-02-28 | — | — | CN | claimed |
| CN-114948852-A | Microneedle system for diagnosis and treatment of brain diseases and preparation method thereof | 深圳先进技术研究院 | 2022-08-30 | — | — | CN | claimed |
| EP-1323422-B1 | Pharmaceutical composition comprising midazolam for buccal administration | SPECIAL PRODUCTS LTD (GB) | 2005-10-26 | — | — | EP | claimed |
| US-6936605-B2 | Pharmaceutical composition | SPECIAL PRODUCTS LIMITED (GB) | 2005-08-30 | — | — | US | claimed |
| WO-2005067893-A2 | PHARMACEUTICAL COMPOSITIONS COMPRISING MIDAZOLAM IN A HIGH CONCENTRATION | MERKUS FRANCISCUS WILHELMUS HE (BE) | 2005-07-28 | — | — | WO | claimed |
| US-20050153956-A1 | Pharmaceutical compositions comprising midazolam in a high concentration | MERKUS FRANCISCUS WILHELMUS H (BE) | 2005-07-14 | — | — | US | claimed |
| WO-2004105767-A1 | PHARMACEUTICAL COMPOSITION BASED ON AGONIST OF BENZODIAZEPINE | SIGMA PHARMA LTDA. (BR) | 2004-12-09 | — | — | WO | claimed |
| US-20040058946-A1 | Abuse-resistant prodrugs of oxycodone and other pharmaceuticals | COLLEGIUM PHARMACEUTICAL, INC. | 2004-03-25 | — | — | US | claimed |
| US-20030130267-A1 | Pharmaceutical composition | SPECIAL PRODUCTS LIMITED | 2003-07-10 | — | — | US | claimed |
| EP-1323422-A1 | Pharmaceutical composition comprising midazolam for buccal administration | Special Products Limited (GB) | 2003-07-02 | — | — | EP | claimed |
| CN-1242934-A | Toxinless chemical for rat eradication | ZHOU LIANGYONG (CN) | 2000-02-02 | — | — | CN | claimed |
| US-4280957-A | Imidazodiazepines and processes therefor | HOFFMANN-LA ROCHE INC. (US) | 1981-07-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030130267-A1 | Pharmaceutical composition | CYP3A5, CYP3A7, CYP3A43 | GABRA1 23/4885GABRG2 36/4885GABRB3 24/4885 |
| US-20040058946-A1 | Abuse-resistant prodrugs of oxycodone and other pharmaceuticals | OPRK1, OPRM1, OPRL1 | GABRA1 618/4885GABRG2 922/4885GABRB3 455/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.